Cancer Center Zürich First Zurich Immuno-Oncology Symposium
Thursday, August 25th, 2016 09.15 – 17.00 h Grosser Hörsaal Ost UniversityHospital Zurich
As Prof. Dr. Rolf Stahel, Chair and Prof. Dr. Michael Weller Deputy Chair both Cancer Center Zürich Cancer Center Zürich are writing in their welcome to the partcipants of the First Zurich Immuno-Oncology Symposium Immunotherapy with immune checkpoint inhibitors has become a reality for patients with metastatic melanoma and patients with advanced non-smallcell lung cancer with progressive disease after first line chemotherapy. Available data indicate patients with many other malignant diseases are likely to benefit from this form of therapy. The advent of immunotherapy brings new opportunities, but also new challenges to physicians advising patients and treating patients. Oncoletter received the permission to videotape this symposium and invites you in the words of Profs. Stahel and Weller to take part in the First Zurich Immuno-Oncology Symposium of the Cancer Center Zürich to familiarize yourself with the new developments.